Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd 2024 AR2
The report outlines the financial and operational performance of Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. for the fiscal year 2024. During the reporting period, the company achieved operating revenue of RMB 74,992,820,000, representing a slight year-on-year decrease of 0.69%, and a net profit attributable to shareholders of RMB 2,835,496,000. The company steadily advanced its key business segments, including Great Southern TCM, Great Health, Great Commerce, and Great Medical Care, while accelerating digital transformation and green manufacturing initiatives. Additionally, the company invested approximately RMB 9.9 million in environmental protection and continued to support rural revitalization and public welfare projects.
Company: Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
Sector: Health Care
Country: China
Year: 2024
Type: AR2
Pages: 435
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
Annual Report
The report outlines the financial and operational performance of Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. for the fiscal year 2024. During the reporting period, the company achieved operating revenue of RMB 74,992,820,000, representing a slight year-on-year decrease of 0.69%, and a net profit attributable to shareholders of RMB 2,835,496,000. The company steadily advanced its key business segments, including Great Southern TCM, Great Health, Great Commerce, and Great Medical Care, while accelerating digital transformation and green manufacturing initiatives. Additionally, the company invested approximately RMB 9.9 million in environmental protection and continued to support rural revitalization and public welfare projects.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Employees